Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

WELIREG 40 mg film-coated tablets {equilateral_black_triangle}

Active Ingredient:
belzutifan
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

WELIREG DHPC communication: Risk of Hypoxia related adverse events

{healthcare_pro_orange} For Healthcare Professionals

The DHPC letter serves to inform HCPs that a patient alert card should be provided to all UK patients prescribed Welireg to specifically provide guidance related to the risks of treatment associated hypoxia.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Merck Sharp & Dohme (UK) Limited
Company image
Address
120 Moorgate, London, EC2M 6UR, UK
WWW
http://www.msd-uk.com/
Telephone
+44 (0)208 154 8000 (all hours)
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 154 8001